The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects "SPIRE-2"

Terminated

Phase 3 Results N/A

Summary of Purpose

This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and unstable angina requiring urgent revascularization in high risk subjects who are receiving... Trial Stopped: See Detailed Description

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 25 October 2017.

1 Oct 2013 21 Oct 2013 1 Apr 2017 1 Apr 2017 1 Oct 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Prevention
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts

  • Pfizer CT.gov Call Center